References
- Armani E, Amari G, Rizzi A, et al. (2014). A novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases. J Med Chem 57:793–816
- Daniels JS, Espina R, Cao K, et al. (2007). Species-specific, P450- and sulfotransferase-mediated novel ring contraction of a naphthyridine-N-oxide compound in Cynomolgus monkey. Chem Res Toxicol 20:1709–17
- Ghiglieri A, Messina M, Cenacchi V, et al. Tissue distribution and elimination of [14C]-CHF 6001 in rats. Unpublished data
- Hatzelmann A, Schudt C. (2001). Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297:267–79
- Houghton LA, Atkinson W, Whorwell PJ, et al. (2006). Effects of Cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and pH, and orocecal and colonic transit: two single-center, randomized, double-blind, placebo-controlled, two-part crossover studies in healthy volunteers. Clin Ther 28:569–81
- Lipworth BJ. (2005). Phosphodiesterases-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365:167–75
- Rabe KF. (2011). Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 163:53–67
- Spina D. (2003). Phosphodiesterase-4 inhibitor in the treatment of inflammatory lung disease. Drugs 63:2575–94
- Spina D. (2008). PDE4 inhibitors: current status. Br J Pharmacol 155:308–15
- Stearns RA, Ortiz de Montellano PR. (1985). Cytochrome P-450 catalyzed oxidation of quadricyclane. Evidence for a radical cation intermediate. J Am Chem Soc 107:4081–2
- Torphy T, Page C. (2000). Phosphodiesterases: the journey towards therapeutics. Trend Pharmacol Sci 21:157–9
- Villetti G, Carnini C, Battipaglia L, et al. (2015). CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration – in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window. J Pharmacol Exp Ther 352:568–78
- Yin W, Mitra K, Stearns RA, et al. (2004). Conversion of the 2,2,6,6-tetramethylpiperidine moiety to a 2,2 dimethylpyrrolidine by cytochrome P450: evidence for a mechanism involving nitroxide radicals and heme iron. Biochemistry 43:5455–66